NASDAQ:SABS

Sab Biotherapeutics Stock Earnings Reports

etoro logo Buy SABS
*Your capital is at risk
$3.36
-0.120 (-3.45%)
At Close: Jun 03, 2026

SAB Biotherapeutics Earnings Calls

Mar 31, 2026
-$0.350 (-75.00%)
Release date May 12, 2026
EPS estimate -$0.200
EPS actual -$0.350
EPS Surprise -75.00%
Revenue estimate 125K
Revenue actual -
Dec 31, 2025
-$0.460 (-187.50%)
Release date Mar 09, 2026
EPS estimate -$0.160
EPS actual -$0.460
EPS Surprise -187.50%
Revenue estimate 100K
Revenue actual -
Sep 30, 2025
-$0.210 (64.41%)
Release date Nov 14, 2025
EPS estimate -$0.590
EPS actual -$0.210
EPS Surprise 64.41%
Revenue estimate 100K
Revenue actual -
Jun 30, 2025
-$1.09 (-32.93%)
Release date Aug 07, 2025
EPS estimate -$0.82
EPS actual -$1.09
EPS Surprise -32.93%
Revenue estimate 83.33K
Revenue actual -

Last 4 Quarters for SAB Biotherapeutics

Below you can see how SABS performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

SIGN UP FREE
or
Creating an account or logging in means you agree to StockInvest.us Terms of Use and Privacy Policy.
Jun 30, 2025 Missed
Release date Aug 07, 2025
Price on release $2.23
EPS estimate -$0.82
EPS actual -$1.09
EPS surprise -32.93%
Date Price
Aug 01, 2025 $2.23
Aug 04, 2025 $2.28
Aug 05, 2025 $2.30
Aug 06, 2025 $2.19
Aug 07, 2025 $2.23
Aug 08, 2025 $2.20
Aug 11, 2025 $2.02
Aug 12, 2025 $2.16
Aug 13, 2025 $2.15
4 days before 0%
4 days after -3.59%
On release day -1.35%
Change in period -3.59%
Sep 30, 2025 Beat
Release date Nov 14, 2025
Price on release $3.24
EPS estimate -$0.590
EPS actual -$0.210
EPS surprise 64.41%
Date Price
Nov 10, 2025 $3.20
Nov 11, 2025 $3.27
Nov 12, 2025 $3.41
Nov 13, 2025 $3.10
Nov 14, 2025 $3.24
Nov 17, 2025 $3.50
Nov 18, 2025 $3.91
Nov 19, 2025 $3.83
Nov 20, 2025 $3.80
4 days before 1.25%
4 days after 17.28%
On release day 8.02%
Change in period 18.75%
Dec 31, 2025 Missed
Release date Mar 09, 2026
Price on release $3.84
EPS estimate -$0.160
EPS actual -$0.460
EPS surprise -187.50%
Date Price
Mar 03, 2026 $3.89
Mar 04, 2026 $3.93
Mar 05, 2026 $3.81
Mar 06, 2026 $3.79
Mar 09, 2026 $3.84
Mar 10, 2026 $4.10
Mar 11, 2026 $4.58
Mar 12, 2026 $4.59
Mar 13, 2026 $4.15
4 days before -1.29%
4 days after 8.07%
On release day 6.77%
Change in period 6.68%
Mar 31, 2026 Missed
Release date May 12, 2026
Price on release $3.62
EPS estimate -$0.200
EPS actual -$0.350
EPS surprise -75.00%
Date Price
May 06, 2026 $3.80
May 07, 2026 $4.09
May 08, 2026 $4.11
May 11, 2026 $3.72
May 12, 2026 $3.62
May 13, 2026 $3.96
May 14, 2026 $3.89
May 15, 2026 $3.70
May 18, 2026 $3.56
4 days before -4.74%
4 days after -1.66%
On release day 9.39%
Change in period -6.32%

SAB Biotherapeutics Earnings History

Earnings Calendar

FAQ

When is the earnings report for SABS?
SAB Biotherapeutics, Inc. (SABS) has scheduled its earnings report for Aug 06, 2026 after the markets close.

What is the SABS price-to-earnings (P/E) ratio?
SABS P/E ratio as of Jun 03, 2026 (TTM) is -451.67.

What is the SABS EPS forecast?
The forecasted EPS (Earnings Per Share) for SAB Biotherapeutics, Inc. (SABS) for the first fiscal quarter 2026 is -$0.290.

What are SAB Biotherapeutics, Inc.'s retained earnings?
On its balance sheet, SAB Biotherapeutics, Inc. reported retained earnings of $0 for the latest quarter ending Mar 31, 2026.

What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Click to get the best stock tips daily for free!
ABOUT SAB BIOTHERAPEUTICS, INC.
SAB Biotherapeutics
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ tran...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE